Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The CONVINCE randomized controlled trial, conducted in end-stage kidney disease (ESKD) hemodialysis patients, found a slower decline in patient-reported health status for those receiving hemodiafiltration versus high-flux hemodialysis, particular improvements were observed in physical and cognitive function, pain interference and social participation. There is clinical interest in whether these benefits of hemodiafiltration are modified by age, sex, time on dialysis, diabetes and cardiovascular disease, and type of vascular access.
The CONVINCE trial data was used to perform prespecified subgroup analyses looking at the comparative effects of hemodiafiltration versus hemodialysis on quality of life domains with PROMIS short forms (Physical Function, Fatigue, Pain Interference, Sleep Disturbance, Anxiety, Cognitive Function, Depression, Ability to Participate in Social Roles and Activities) by the following subgroups: age (>65, 50-65, <50 years), sex (male/female), time on dialysis (>5, 2-5, <2 years), diabetes (yes/no) and cardiovascular disease (yes/no), and type of vascular access (catheter/graft vs arteriovenous fistula). Patient-reported outcome data were collected every 3 months over the course of the trial. We tested subgroup interactions in a longitudinal linear mixed model.
From 1360 randomized patients, data were available for 1211 patients (89%). The effect of hemodiafiltration on sleep disturbance was significantly better for patients with arteriovenous fistula as compared to those with catheters/grafts (p=0.026). Patients who had been on dialysis for more than 5 years had better physical function with hemodiafiltration (p = 0.028). Treatment with hemodiafiltration had a stronger effect on pain interference for those who were <50 years (p =0.044) and the effects on cognitive function were better in those who had no history of cardiovascular disease (p = 0.048) (see Figure).
The CONVINCE trial found significant effects of hemodiafiltration on specific domains of health status in ESKD patients compared to high-flux hemodialysis. While these benefits varied slightly between subgroups, possibly due to multiple statistical comparisons or underpowered sample, they may reflect meaningful differences worthy of further investigation. Integrating PROMIS in future trials and clinical routine care will help clarify and expand these findings.
